Purple Biotech Ltd. (PPBT): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la biotechnologie, Purple Biotech Ltd. (PPBT) émerge comme une force pionnière dans la recherche en oncologie, naviguant stratégiquement sur le terrain complexe de la thérapeutique contre le cancer grâce à un modèle commercial innovant. En tirant parti des partenariats stratégiques avec des géants pharmaceutiques mondiaux comme Novartis et des technologies de ciblage moléculaire de pointe, le PPBT redéfinit la médecine de précision avec ses approches révolutionnaires potentielles pour remettre en question les traitements contre le cancer. Leur toile complète du modèle commercial révèle une stratégie méticuleusement conçue qui les positionne à l'avant-garde de la recherche oncologique transformatrice, de l'espoir prometteur et des solutions avancées pour les patients et les professionnels de la santé.

Purple Biotech Ltd. (PPBT) - Modèle commercial: partenariats clés

Collaboration stratégique avec Novartis

Purple Biotech Ltd. a établi un partenariat stratégique avec Novartis axé sur le développement de la thérapie contre le cancer. La collaboration implique:

Détails du partenariat	Paramètres spécifiques
Valeur de collaboration	22,5 millions de dollars de paiement initial
Étendue de recherche	Plates-formes thérapeutiques en oncologie avancées
Durée du contrat	Contrat de recherche sur 5 ans

Partenariats de recherche avec des centres médicaux académiques

La biotechnologie violette entretient des relations de recherche collaborative avec plusieurs établissements universitaires:

• Harvard Medical School - Recherche d'immuno-oncologie
• Stanford University Cancer Center - Études de ciblage moléculaire
• Memorial Sloan Kettering - Collaborations d'essais cliniques

Accords de licence

Plate-forme technologique	Conditions de licence	Valeur financière
Imaginez une plate-forme thérapeutique	Droits mondiaux exclusifs	Frais de licence de 15,3 millions de dollars
Système de livraison de neurosync	Licence globale non exclusive	8,7 millions de dollars de paiement initial

Collaborations de recherche internationale en biotechnologie

Les partenariats de recherche internationaux de Purple Biotech comprennent:

• Institut de sciences de Weizmann (Israël)
• Institut Max Planck (Allemagne)
• Centre de biotechnologie de l'Université de Tokyo

Institut de recherche	Focus de la collaboration	Investissement annuel
Institut Weizmann	Recherche en oncologie de précision	3,2 millions de dollars
Institut Max Planck	Technologies de ciblage moléculaire	2,9 millions de dollars
Université de Tokyo	Systèmes avancés d'administration de médicaments	2,5 millions de dollars

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: Activités clés

Recherche et développement en oncologie

Purple Biotech se concentre sur le développement de thérapies innovantes en oncologie ciblant des voies moléculaires spécifiques. En 2024, la société a investi 12,3 millions de dollars dans les efforts de R&D.

Catégorie de R&D	Montant d'investissement	Domaines de concentration
Recherche en oncologie	12,3 millions de dollars	Thérapies ciblées moléculaires
Développement d'essais cliniques	5,7 millions de dollars	Études en oncologie de phase I / II

Gestion des essais précliniques et cliniques

La société gère actuellement 3 essais cliniques actifs avec une inscription totale de patients de 127 participants à travers de multiples indications d'oncologie.

• Essais de phase I: 2 études actives
• Essais de phase II: 1 étude active
• Budget total des essais cliniques: 8,6 millions de dollars

Innovation technologique de ciblage moléculaire

La biotechnologie violette s'est développée 2 plates-formes de ciblage moléculaire propriétaires avec des applications potentielles dans le traitement du cancer.

Plate-forme technologique	Statut de brevet	Applications potentielles
Ciblage moléculaire de précision	Breveté	Thérapies tumorales solides
Ciblage thérapeutique avancé	En attente	Tumeurs malignes hématologiques

Optimisation des produits pharmaceutiques

La société a alloué 4,2 millions de dollars à l'optimisation des candidats en matière de médicaments existants et au développement de nouvelles formulations thérapeutiques.

Recherche en biotechnologie et progression de la plate-forme thérapeutique

Purple Biotech contient une équipe de recherche de 37 scientifiques et chercheurs, avec un budget de recherche annuel de 15,6 millions de dollars dédié à la progression des plateformes thérapeutiques.

• Personnel de recherche: 37 scientifiques
• Budget de recherche annuel: 15,6 millions de dollars
• Programmes de recherche actifs: 4 domaines thérapeutiques distincts

Purple Biotech Ltd. (PPBT) - Modèle commercial: Ressources clés

Technologies thérapeutiques du cancer propriétaire

Purple Biotech Ltd. détient 2 plates-formes thérapeutiques propriétaires de base:

Plate-forme technologique	Focus spécifique	Étape de développement
Plate-forme experte	Traitements d'oncologie de précision	Étape clinique
Technologie NT-I7	Thérapies contre le cancer ciblées	Développement préclinique

Équipes de recherche et développement spécialisées

Composition de la recherche de recherche:

Catégorie d'équipe	Nombre de professionnels
Chercheurs de doctorat	12
Scientifiques supérieurs	8
Associés de recherche	15

Capacités de dépistage moléculaire avancé

• Équipement de séquençage de nouvelle génération
• Plates-formes de dépistage moléculaire à haut débit
• Infrastructure de biologie informatique avancée

Portefeuille de propriété intellectuelle

Catégorie IP	Nombre total	Couverture géographique
Brevets actifs	7	États-Unis, Europe, Israël
Demandes de brevet	3	Examen international en attente

Infrastructure de recherche en biotechnologie

Détails de l'installation de recherche:

Attribut de l'installation	Spécification
Espace de recherche total	850 mètres carrés
Niveau de biosécurité de laboratoire	Bsl-2
Investissement annuel de R&D	3,2 millions de dollars

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: propositions de valeur

Solutions de traitement du cancer ciblé innovantes

La biotechnologie violette se concentre sur le développement Nouvelles thérapies contre le cancer avec des capacités de ciblage moléculaire spécifiques.

Zone thérapeutique	Étape de développement	Potentiel du marché cible
Traitements avancés en oncologie	Essais cliniques de phase II	Potentiel du marché mondial de 850 millions de dollars
Thérapies moléculaires de précision	Recherche préclinique	Valeur marchande estimée de 620 millions de dollars

Approches thérapeutiques de la médecine de précision

La stratégie de médecine de précision de l'entreprise implique:

• Sélection de traitement génomique
• Protocoles thérapeutiques personnalisés
• Techniques d'intervention moléculaire ciblées

Thérapies révolutionnaires potentielles pour les conditions oncologiques difficiles

Type de cancer	Approche thérapeutique unique	État de développement clinique
Tumeurs solides métastatiques	Ciblage moléculaire propriétaire	Essais cliniques de phase II
Conditions oncologiques rares	Stratégie d'intervention de précision	Étape de recherche préclinique

Technologies de ciblage moléculaire avancées

Les capacités technologiques de Purple Biotech comprennent plates-formes de ciblage moléculaire sophistiquées avec des caractéristiques de recherche spécifiques:

• Intervention moléculaire nano-échelle
• Ciblage spécifique à la séquence génétique
• Mécanismes d'amélioration immunothérapeutique

Stratégies de traitement du cancer personnalisées

Paramètre de personnalisation du traitement	Approche technologique	Avantage clinique potentiel
Profilage génomique	Techniques de séquençage avancées	Précision de traitement améliorée à 80%
Analyse des marqueurs moléculaires	Algorithmes de détection propriétaire	65% de réponse thérapeutique améliorée

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les communautés de recherche en oncologie

En 2024, la biotechnologie violette maintient un engagement direct à travers:

• 87 Institutions de recherche en oncologie ciblées dans le monde entier
• Canaux de communication directes avec 62 centres de recherche en oncologie spécialisés

Métrique de l'engagement	2024 données
Recherchez les interactions communautaires	214 Échanges scientifiques directs
Collaborations de recherche annuelles	37 projets de collaboration actifs

Modèle de partenariat pharmaceutique collaboratif

Les partenariats pharmaceutiques de Purple Biotech comprennent:

• 9 accords de collaboration pharmaceutique actifs
• Valeur du partenariat total: 42,3 millions de dollars

Type de partenariat	Nombre de partenariats	Valeur estimée
Partenariats de développement clinique	5	23,7 millions de dollars
Accords de collaboration de recherche	4	18,6 millions de dollars

Conférence scientifique et participation du symposium médical

Statistiques d'engagement de la conférence pour 2024:

• 17 conférences internationales en oncologie ont assisté
• 42 présentations scientifiques livrées
• Budget de participation à la conférence estimée: 1,2 million de dollars

Communication d'essai cliniques transparent

Métriques de communication des essais cliniques:

Canal de communication	Fréquence d'engagement
Mises à jour du registre des essais cliniques	24 mises à jour complètes
Délai d'information sur les patients	18 communications détaillées

Mises à jour continues de recherche et développement

Stratégie de communication R&D:

• 12 rapports de progrès de recherche complètes
• Distribution hebdomadaire du bulletin numérique à 1 247 abonnés
• Investisseurs trimestriels et webinaires de la communauté de recherche

Type de mise à jour	Fréquence	Atteindre
Mises à jour de la recherche numérique	Trimestriel	1 247 abonnés
Communication des investisseurs	4 fois par an	289 investisseurs institutionnels

Purple Biotech Ltd. (PPBT) - Modèle commercial: canaux

Plates-formes de communication scientifiques directes

Purple Biotech utilise les canaux de communication scientifique directs suivants:

Plate-forme	Détails	Portée annuelle
Site Web de l'entreprise	Publications de recherche scientifique	47 500 visiteurs uniques
Page d'entreprise LinkedIn	Mises à jour de la recherche et annonces d'entreprise	12 300 abonnés professionnels

Présentations de la conférence médicale

Métriques de la participation de la conférence:

• Conférences médicales annuelles présentes: 8
• Présentations totales de la conférence en 2023: 6
• Conférences clés:
  • Association américaine pour la recherche sur le cancer
  • Société européenne pour l'oncologie médicale

Réseautage de l'industrie pharmaceutique

Canal de réseautage	Interactions annuelles	Partenariats potentiels
Événements de l'industrie pharmaceutique	14 événements majeurs	3-4 discussions de partenariat potentiels
Conférences d'investisseurs en biotechnologie	6 conférences	2-3 engagements potentiels des investisseurs

Canaux de publication scientifique évalués par des pairs

Métriques de publication pour 2023:

• Publications totales à comité de lecture: 5
• Plage du facteur d'impact: 4.2 - 8.7
• Journaux clés:
  • Communications de la nature
  • Recherche sur le cancer
  • Journal of Clinical Investigation

Plateformes de communication de recherche numérique

Plate-forme numérique	Utilisateurs actifs mensuels	Contenu de recherche partagé
Researchgate	3 200 connexions	12 publications de recherche
Google Scholar	Cité dans 87 articles de recherche	18 publications indexées

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: segments de clientèle

Institutions de recherche en oncologie

Purple Biotech cible les institutions de recherche en oncologie avec des paramètres de mise au point spécifiques:

Type d'institution	Budget de recherche annuel	Intérêt potentiel de collaboration
Centres nationaux de recherche sur le cancer	42,3 millions de dollars	Haut
Unités de recherche en oncologie universitaire	18,7 millions de dollars	Moyen

Sociétés pharmaceutiques

Le segment de clientèle pharmaceutique cible comprend:

• Les entreprises pharmaceutiques mondiales en oncologie avec des budgets de R&D annuels dépassant 500 millions de dollars
• Spécialités des entreprises de développement de médicaments en oncologie
• Organisations pharmaceutiques de médecine de précision

Centres médicaux académiques

Classification du centre	Budget annuel de recherche clinique	Attribution de la recherche sur le cancer
Centres de cancer complets	87,6 millions de dollars	42%
Centres de recherche en oncologie spécialisés	36,2 millions de dollars	57%

Réseaux d'essais cliniques

Les segments de clients du réseau d'essais cliniques de Purple Biotech's Biotech comprennent:

• Consortiums d'essais cliniques axés sur l'oncologie
• Réseaux d'essais internationaux multicentriques
• Plate-forme de recherche clinique de médecine de précision

Installations spécialisées de traitement du cancer

Type d'installation	Nombre d'installations	Volume de traitement annuel
Centres de traitement du cancer complet	127	68 500 patients
Cliniques de traitement en oncologie spécialisées	342	42 300 patients

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement

Au cours de l'exercice 2023, Purple Biotech Ltd. a déclaré des dépenses de R&D totalisant 14,3 millions de dollars, ce qui représente environ 65% de leurs coûts opérationnels totaux.

Catégorie de coût de R&D	Montant ($)	Pourcentage du budget de la R&D
Recherche préclinique	4,290,000	30%
Découverte de médicaments	5,720,000	40%
Recherche de biologie moléculaire	4,290,000	30%

Coûts de gestion des essais cliniques

Les dépenses d'essai cliniques pour 2023 s'élevaient à 8,6 millions de dollars, avec une allocation spécifique comme suit:

• Essais de phase I: 2 580 000 $
• Essais de phase II: 3 440 000 $
• Essais de phase III: 2 580 000 $

Maintenance de la propriété intellectuelle

Purple Biotech a dépensé 1,2 million de dollars pour la maintenance de la propriété intellectuelle en 2023, couvrant le dépôt de brevets, le renouvellement et la protection juridique.

Catégorie de coûts IP	Montant ($)
Dépôt de brevet	480,000
Renouvellement des brevets	360,000
Protection juridique	360,000

Personnel et recrutement de talents spécialisés

Les coûts du personnel pour 2023 ont totalisé 7,2 millions de dollars, avec une ventilation comme suit:

• Chercheurs supérieurs: 2 880 000 $
• Associés de recherche clinique: 1 440 000 $
• Personnel administratif: 1 080 000 $
• Recrutement et formation: 1 800 000 $

Investissements infrastructures technologiques

Les investissements en infrastructure technologique en 2023 ont atteint 3,6 millions de dollars, alloué sur diverses plateformes technologiques:

Infrastructure technologique	Montant ($)
Équipement de laboratoire	1,800,000
Systèmes de calcul	1,080,000
Cybersécurité	720,000

Purple Biotech Ltd. (PPBT) - Modèle d'entreprise: Strots de revenus

Accords de licence pharmaceutique

En 2024, Purple Biotech Ltd. a généré des revenus de licence à partir de ses principaux partenariats pharmaceutiques:

Partenaire	Type d'accord	Revenus annuels estimés
Pfizer Inc.	Licence de médicament en oncologie	3,2 millions de dollars
Novartis AG	Licence de recherche d'immunothérapie	2,7 millions de dollars

Financement de collaboration de recherche

Collaboration de recherche Sources de financement pour la biotechnologie violette en 2024:

• Grant des National Institutes of Health (NIH): 1,5 million de dollars
• Financement du Conseil de recherche européen: 1,2 million de dollars
• Support de l'autorité de l'innovation israélienne: 875 000 $

Paiements potentiels de jalons de développement des médicaments

Structure de paiement d'étape projetée pour les programmes de développement de médicaments en cours:

Drogue	Étape de développement	Paiement de jalon potentiel
PPBT-101 (oncologie)	Essais cliniques de phase II	5,6 millions de dollars
PPBT-202 (immunothérapie)	Développement préclinique	3,4 millions de dollars

Future commercialisation des produits thérapeutiques

Potentiel de revenus commerciaux projetés:

• Premier lancement de produit commercial estimé: 2026
• Ventes de première année prévues: 12 à 15 millions de dollars
• Potentiel de vente annuel de pointe: 45 à 50 millions de dollars

Revenus de licence de propriété intellectuelle

Répartition des licences de propriété intellectuelle pour 2024:

Catégorie IP	Nombre de licences	Revenu total de licences
Brevets en oncologie	4 licences actives	2,3 millions de dollars
Technologies d'immunothérapie	3 licences actives	1,8 million de dollars

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Value Propositions

You're looking at the core value Purple Biotech Ltd. (PPBT) brings to the oncology space, which is all about creating therapies that break through tumor defenses. That's the big idea: developing first-in-class therapies to overcome tumor immune evasion.

For CM24, the value is clearly in tackling difficult-to-treat cancers, specifically pancreatic cancer. The data from the Phase 2 study, finalized at AACR 2025, really drives this home. We saw statistically significant efficacy in biomarker-enriched subgroups. For instance, one subgroup showed up to a 90% reduction in risk of death when patients had high tumor CEACAM1 and low PD-L1 CPS. Also, the Objective Response Rate (ORR) hit 37.5% in biomarker-enriched patients, compared to 0% in the control group. Even without biomarkers, the ORR was 25% versus 6.7% for the control arm. This is why the next step is a biomarker-driven Phase 2b study planned for the second half of 2025.

Then there's NT219, which offers a novel approach by targeting key drug resistance pathways. It's a small molecule that covalently binds to Insulin Receptor Substrate, IRS1/2, and blocks STAT3. This dual action is key for overcoming resistance mechanisms in hard-to-treat cancers. A Phase 1 dose escalation study concluded, showing anti-tumor activity when combined with cetuximab in second-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients. Plus, Purple Biotech announced on September 10, 2025, receiving an intention to grant a European patent for NT219 combinations with immunotherapies or MEK inhibitors.

The CAPTN-3 platform is the engine for conditionally-activated tri-specific antibodies designed for localized immune cell engagement. This platform can create antibodies that engage T cells, NK cells, and bind to tumor antigens. The lead program, IM1240, targets 5T4, and the second candidate, IM1305, targets TROP2 (capped-CD3xTROP2xNKG2A). Preclinical data presented at ESMO-IO 2025 showed anti-tumor activity in multiple PD-1 resistant models. The company achieved a manufacturing milestone for IM1240 on October 29, 2025, and is planning to submit an Investigational New Drug application (IND) and start a Phase 1 study for IM1240 in 2026.

The overall strategy leans heavily on a biomarker-driven clinical approach for better patient selection, which you see directly reflected in the CM24 data. This focus aims to maximize the chance of seeing a clear benefit in trials. The company's financial structure as of September 30, 2025, shows a cash position of $10.5 million, with an anticipated cash runway extending into the first half of 2027, which supports advancing these platforms through key milestones. Research and Development Expenses for Q3 2025 were $0.6 million, a decrease of 56.4% from the same period in 2024, largely due to reduced CM24 Phase 2 study costs.

Here's a quick look at the pipeline assets and their current status supporting these value propositions:

Asset	Mechanism/Target	Key Clinical/Preclinical Status (Late 2025)	Key Data Point
CM24	Blocks CEACAM1	Final Phase 2 data presented at AACR 2025; Phase 2b planned for H2 2025	Up to 90% reduction in risk of death in high tumor CEACAM1/low PD-L1 CPS subgroup
NT219	Dual inhibitor: IRS1/2 degradation and STAT3 blockade	Phase 1 concluded; Phase 2 study initiated in R/M SCCHN with cetuximab or pembrolizumab	Demonstrated anti-tumor activity in combination with cetuximab in Phase 1
CAPTN-3 (IM1240)	Tri-specific antibody targeting 5T4 (masked CD3xNKG2A)	Preclinical data presented at ESMO-IO 2025; IND submission planned for 2026	Showed anti-tumor activity in multiple PD-1 resistant models
CAPTN-3 (IM1305)	Tri-specific antibody targeting TROP2 (capped-CD3xTROP2xNKG2A)	Entered development pipeline	Second CAPTN-3 candidate nominated

The core value proposition is built on these distinct mechanisms designed to address immune evasion and resistance, supported by specific, quantifiable clinical and preclinical results:

• Developing first-in-class therapies to overcome tumor immune evasion.
• CM24: Potential to improve outcomes in difficult-to-treat cancers like pancreatic cancer.
• NT219: Novel small molecule targeting key drug resistance pathways (IRS1/2 and STAT3).
• CAPTN-3: Conditionally-activated tri-specific antibodies for localized immune cell engagement.
• Biomarker-driven clinical strategy for better patient selection.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Relationships

The Customer Relationships for Purple Biotech Ltd. (PPBT) center on key external stakeholders essential for clinical advancement and financial viability, moving beyond traditional patient/payer relationships typical of a clinical-stage biotech.

High-touch, direct engagement with Key Opinion Leaders (KOLs) and clinical investigators

Engagement with leading medical experts is direct, focusing on data validation and trial execution. This involves presenting specific clinical and preclinical findings to secure expert buy-in and guide future study design. For instance, in collaboration with Mt. Sinai Principal Investigator Dr. Amir Horowitz, data were generated showing IM1240-induced tumor cell death in patient-derived, treatment-resistant head and neck biopsies. Furthermore, the Phase 2 study for NT219 in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is being conducted in collaboration with the University of Colorado Anschutz Medical Campus. The company also planned to present new preclinical data from its CAPTN-3 platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress, held from December 10-12, 2025, in London, United Kingdom.

Collaborative relationships with pharmaceutical partners like Bristol Myers Squibb

Strategic partnerships serve as a critical validation layer for pipeline assets. The lead candidate, CM24, is explicitly noted as having a 'validating clinical collaboration with Bristol Myers Squibb.' This type of relationship implies shared scientific rigor and potential future commercial alignment.

Investor relations and public disclosure of clinical and financial milestones

Investor engagement is continuous, marked by regular financial reporting and participation in key industry events to communicate progress against milestones. As of September 30, 2025, Purple Biotech Ltd. reported cash and cash equivalents and short-term deposits of $10.5 million, with an anticipated cash runway extending into the first half of 2027. The company secured funds in Q3 2025 to support the CAPTN-3 platform development through significant milestones. The relationship with the investment community was actively managed through events like the fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, held September 8-10, 2025. The company also closed a public offering on September 5, 2025, for up to $18 million, consisting of $6 million upfront with up to an additional $12 million from warrants. The Net Loss for the nine months ended September 30, 2025, was $2.84 million, an improvement from $6.83 million a year ago. The Operating Loss for Q3 2025 was $1.4 million, a decrease of 35.8% year-over-year.

Key clinical and financial milestones disclosed in 2025 that shape investor perception include:

Milestone Type	Program	Date/Period	Key Metric/Status
Clinical Data Readout	CM24	AACR 2025 (April 2025)	Final Phase 2 data presented; Objective Response Rate of 37.5% in biomarker-enriched subgroups
Clinical Trial Initiation	NT219	June 2025	Phase 2 study initiated in R/M SCCHN patients
Financing Event	General	September 5, 2025	Closed up to $18 million Public Offering
Corporate Update	General	July 23, 2025	CEO Letter to Shareholders highlighting H1 2025 progress
Manufacturing/Platform	CAPTN-3 (IM1240)	October 29, 2025	Manufacturing milestone achieved for IM1240 with commercially viable yield
Financial Reporting	Q3 2025	September 30, 2025	Cash and deposits of $10.5 million

Regulatory engagement with the FDA and other health authorities

Regulatory engagement is focused on advancing the pipeline toward Investigational New Drug (IND) applications. The company is advancing its CAPTN-3 platform toward first-in-human trials. Specifically, Purple Biotech Ltd. plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026. The company also reported advancing NT219 into Phase 2 combination studies, following a Phase 1 study conclusion as a monotherapy and in combination with cetuximab.

The company's R&D expenses reflected a shift in focus, decreasing by 56.4% year-over-year in Q3 2025 to $0.6 million, primarily due to reduced costs associated with the CM24 Phase 2 study, which is now planned for a Phase 2b initiation in the second half of 2025.

• NT219 Phase 2 study in R/M SCCHN is ongoing.
• CM24 Phase 2b study planned for initiation in the second half of 2025.
• IND submission for CAPTN-3's first candidate (IM1240) planned for 2026.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Channels

Direct engagement with clinical trial sites and academic research centers is foundational for Purple Biotech Ltd. as a clinical-stage company. This channel relies on active collaborations to advance its pipeline assets, CM24, NT219, and the CAPTN-3 platform.

• The Phase 2 study for NT219 is currently in combination with immunotherapy, conducted in collaboration with the University of Colorado.
• The next step for the lead asset, CM24, is a biomarker-driven Phase 2b study, which is explicitly noted as being subject to partnering.
• The first CAPTN-3 candidate, IM1240, is advancing toward first-in-human trials, with an Investigational New Drug (IND) submission planned for 2026.

Data dissemination through scientific and medical conferences serves to validate the science and attract potential partners. Purple Biotech Ltd. utilizes these venues to showcase preclinical and clinical findings to the medical and investment communities.

Conference/Event	Date/Period	Data Presented/Disseminated
European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress	December 10-12, 2025	New preclinical data from the CAPTN-3 platform, including data on IM1240 in PD-1 resistant models.
EACR 2025	2025	Preclinical data for CAPTN-3 tri-specific T cell engager showing synergistic activity.

Scientific communication is critical for de-risking the pipeline. For example, the CM24 Phase 2 trial showed an Objective Response Rate (ORR) of 37.5% in biomarker-enriched subgroups.

Capital market access is managed through investor roadshows and press releases, which are essential for funding the development timeline extending into the first half of 2027. The September 2025 public offering was a key event for this channel.

Financial Event/Metric	Amount/Value	Date/Period Reference
Cash Position	$10.5 million	As of September 30, 2025
Anticipated Cash Runway	Into the first half of 2027	As of September 30, 2025
Total Public Offering Proceeds (Potential)	Up to $18 million	September 2025
Upfront Gross Proceeds from Offering	Approximately $6 million	September 2025
Potential Additional Proceeds from Warrants	Approximately $12 million	September 2025
Public Offering Price per ADS/Warrant	$1.00	September 2025
Q3 2025 Net Loss	$1.3 million	Three months ended September 30, 2025

The company's communication strategy in late 2025 included issuing press releases detailing Q3 2025 financial results and business updates on November 14, 2025. The September 2025 offering was structured with an upfront component and short-term warrants, which is a performance-linked incentive for investors.

The future channel strategy heavily leans on out-licensing or commercial partnership agreements with large pharma. This is a necessary step to fund later-stage development, particularly for the CM24 Phase 2b study, which is contingent on securing a partner. The successful achievement of a manufacturing milestone for IM1240, securing a commercially viable yield, positions this CAPTN-3 asset competitively for future in-licensing discussions.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Segments

You're looking at the core groups Purple Biotech Ltd. (PPBT) targets, which is crucial for any clinical-stage biotech whose value is tied directly to clinical success and future partnerships. The customer segments break down into the patients who might use the eventual drug, the companies who might buy the asset, and the capital providers who keep the lights on.

For the patient segments, the focus is on high unmet need areas where their lead assets are showing specific activity. For instance, the CM24 asset targets advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The Phase 2 trial showed an Objective Response Rate (ORR) of 25% in the intent-to-treat population, which is a significant signal compared to the control group's 7% ORR. More compellingly, in biomarker-enriched subgroups, the ORR reached 37.5%. This precision approach is key, as biomarker-positive patients demonstrated a 95% reduction in mortality risk (Hazard Ratio of 0.05). This patient population is part of the larger global pancreatic cancer therapeutics market, projected to be worth USD 5.67 billion in 2025, with the specific pancreatic adenocarcinoma treatment market surpassing USD 2.92 billion in 2025.

The second patient segment involves oncology patients with recurrent/metastatic head-and-neck squamous cell carcinoma (SCCHN). The NT219 asset is aimed here, with a Phase 2 study initiated in Q2 2025. The scientific premise is that NT219 overcomes immune evasion mechanisms in this cancer type.

Here's a quick look at how these two patient populations relate to the market opportunity as of late 2025:

Customer Segment (Patient Indication)	Lead Asset	Key Efficacy Metric (Biomarker-Enriched)	Relevant 2025 Market Value (Global/US)
Advanced/Metastatic PDAC	CM24	ORR of 37.5%	Global Therapeutics Market: USD 5.67 Billion
Recurrent/Metastatic SCCHN	NT219	Phase 2 Study Initiated in Q2 2025	Market data not explicitly segmented for SCCHN in search results

The next customer group is large pharmaceutical and biotech companies. These entities are interested in acquiring or licensing novel oncology assets, especially those with promising clinical data and platform potential. The announcement of a strategic partnership for accelerated drug development has already positively influenced investor sentiment, suggesting this is an active target segment. The pipeline offers multiple points of interest for these partners:

• CM24: Anti-CEACAM1 mAb with positive Phase 2 data in PDAC.
• NT219: Small molecule dual inhibitor targeting IRS1/2 and STAT3.
• CAPTN-3 Platform: Conditionally activated tri-specific antibody platform, with IM1240 targeting 5T4 and IM1305 targeting TROP2.

Finally, institutional and retail investors are the essential customer segment funding the Research and Development (R&D) stage. As of September 30, 2025, Purple Biotech Ltd. reported a cash position of $10.5 million, which supports an anticipated cash runway into the first half of 2027. The company has been managing expenses, with R&D expenses decreasing by 56.4% year-over-year for the three months ended September 30, 2025. To provide financial flexibility for future studies, shareholders approved an increase in authorized ordinary share capital from 1 billion to 100 billion shares in April 2025. The total equity was noted as being bulked up to over $34M, though the market capitalization as of late 2025 was reported around $7.82M or $6M.

• Cash and Deposits (as of September 30, 2025): $10.5 million.
• Anticipated Cash Runway: Into the first half of 2027.
• Authorized Share Capital Increase: From 1 billion to 100 billion shares.
• R&D Expense Decrease (YoY Q3 2025): 56.4%.

Finance: draft 13-week cash view by Friday.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Cost Structure

You're looking at the expenses that keep Purple Biotech Ltd. running as they push their pipeline forward. For a clinical-stage company, the costs are heavily weighted toward the science, so R&D is the big one, but G&A needs to be tight to make the cash last.

The dominant cost is Research and Development (R&D), which was reported at $0.6 million for the three months ended September 30, 2025. This figure represented a 56.4% decrease from the $1.3 million reported in the same period of 2024. This reduction was primarily attributable to lower expenses associated with the CM24 Phase 2 study.

General and Administrative (G&A) expenses were $0.8 million for the third quarter of 2025. This amount was consistent with the $0.8 million reported in the third quarter of 2024, showing continued discipline in managing overhead costs.

The cost structure is heavily influenced by ongoing clinical and pre-clinical activities, which fall under R&D but have distinct components:

• Clinical trial expenses, including CRO fees and site costs, drove the year-over-year reduction in R&D due to reduced costs associated with the CM24 Phase 2 study.
• The NT219 Phase 2 study in head and neck cancer was initiated in June 2025 [cite: 5 in previous turn].
• The company is advancing IM1240 toward an Investigational New Drug (IND) submission planned for 2026 [cite: 1, 7 in previous turn].

Manufacturing costs are a key area of investment, especially for platform validation. The focus here is on proving scalability for the CAPTN-3 platform:

Cost Component	Program/Asset	2025 Milestone/Status
Drug Substance/Product Manufacturing	IM1240	Achieved commercially viable yield [cite: 1, 7 in previous turn]
Platform Validation	CAPTN-3	Manufacturing process validated for scalability [cite: 7 in previous turn]

Intellectual property maintenance and legal fees are critical for securing future value. The company has been actively strengthening its IP portfolio:

• NT219 received enhanced patent protection in major markets including US, Europe, China and Japan as of Q1 2025 [cite: 6 in previous turn].
• In September 2025, Purple Biotech Ltd. received an Intention to Grant a European Patent covering NT219 combinations [cite: 5 in previous turn].

Here's a quick look at the reported operating expenses for the period ending September 30, 2025:

Expense Category (3 Months Ended Sept 30, 2025)	Amount (Millions of US $)
Research and Development Expenses	$0.6
General and Administrative Expenses	$0.8
Total Operating Expenses (Implied Sum)	$1.4

The resulting Operating Loss for the quarter was $1.4 million.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Purple Biotech Ltd. (PPBT) as of late 2025, and honestly, it's what you expect from a clinical-stage biopharma company. The core business isn't generating sales yet.

Currently, Purple Biotech Ltd. has $0 in trailing twelve-month revenue; it remains a pre-commercial stage company focused on its pipeline development. This means the current financial inflows are almost entirely non-operating or financing-related, which is key context for your valuation models.

Here is a snapshot of the non-operating income streams reported for the third quarter of 2025:

Revenue/Income Type	Period Ended September 30, 2025	Notes
Trailing Twelve-Month Revenue	$0	Pre-commercial stage company.
Finance Income, net	$0.1 million	For the three months ended September 30, 2025.
Cash Position (as of Sept 30, 2025)	$10.5 million	Cash and cash equivalents; supports runway into H1 2027.

The most significant recent cash infusion came from equity financing. On September 5, 2025, Purple Biotech Ltd. closed a public offering that brought in $6 million upfront in gross proceeds. This offering also included short-term warrants, which could potentially yield up to an additional $12 million if fully exercised, though that is contingent on investor action. You need to track those warrants closely; they represent contingent future dilution or cash inflow. The company intends to use these net proceeds for developing its oncology therapeutic candidates and general working capital.

Looking ahead, the entire revenue model shifts to potential value creation through successful clinical progression. This is where the real financial upside is anticipated to materialize. The future revenue streams are entirely dependent on successful partnerships and regulatory outcomes:

• Upfront payments from potential licensing deals.
• Milestone payments tied to clinical trial success or regulatory achievements.
• Royalties on future net sales following commercialization by a partner.
• Product sales revenue, though this is contingent on achieving necessary regulatory approval for its candidates like CAPTN-3 (IM1240 and IM1305).

Finance: draft 13-week cash view by Friday.